Method of treatment of cattle with strongylatosis of gastrointestinal tract

FIELD: veterinary medicine.

SUBSTANCE: method comprises the use of encapsulated fenbendazol. Sodium carboxymethyl cellulose is used as coating of the microcapsules. The microcapsules are obtained by the physico-chemical method of nonsolvent addition using two precipitators - carbinol and cyclohexanol. The ratio of core/polymer is 1:3. The preparation is given to animals at a dose of 22.5 mg/kg (15 mg/kg as active agent) as a single dose.

EFFECT: method is simple to use and is highly effective in the treatment of cattle with strongylatosis.

1 tbl

 

The invention relates to the field of veterinary medicine, and in particular the treatment of cattle at strangelets.

Currently, the closest is a method of treatment of cattle from strangulation using albendazole and native fenbendazol (Arkhipov I.A. Anthelmintic: pharmacology and applications, - M, 2009, 405 S.).

The disadvantage of these drugs is their low solubility in water, which leads to difficulties applying for animals.

The technical problem is to simplify the process of treating animals with simultaneous relief of application of anthelmintic due to new dosage forms that can completely dissolve in water, which increases the effectiveness of treatment.

The solution of the technical problem is achieved by using encapsulated fenbendazol, and as the shell of the microcapsules used sodium carboxymethylcellulose when receiving physical-chemical method for the deposition nerastvorim using two precipitators - carbinol and cyclohexanol.

A distinctive feature is the use of sodium carboxymethylcellulose as the shell of the microcapsules, fenbendazol as their cores, and the use of two precipitators - carbinol and cyclohexanol.

The result of the proposed method are in the doctrine of microcapsules of fenbendazol in the sodium carboxymethyl cellulose at 25°C for 20 minutes. The output of the microcapsules is over 90%.

EXAMPLE 1. Obtaining microcapsules of fenbendazol with the dissolution of the drug in dioxane, the ratio of the core/polymer 1:3.

100 mg of fenbendazol dissolved in 1 ml of dioxane and the resulting mixture was dispersed in a solution of sodium carboxymethylcellulose in cyclohexanol containing the specified 300 mg of the polymer in the presence of 0.01 g of the drug A under stirring about 1000/sec. Then poured 2 ml carbinol and 1 ml of distilled water. The resulting suspension is filtered and dried at room temperature.

Received 0,396 g white to yellowish powder. The yield was 99%.

EXAMPLE 2. Obtaining microcapsules of fenbendazol with the dissolution of the drug in dimethyl sulfoxide (DMSO), the ratio of the core/polymer 1:3.

100 mg of fenbendazol dissolved in 1 ml DMSO and the mixture was dispersed in a solution of sodium carboxymethylcellulose in cyclohexanol containing the specified 300 mg of the polymer in the presence of 0.01 g of the drug A under stirring about 1000/sec. Then poured 2 ml carbinol and 1 ml of distilled water. The resulting suspension is filtered and dried at room temperature.

Received 0,396 g white to yellowish powder. The yield was 99%.

EXAMPLE 3. Obtaining microcapsules of fenbendazol with the dissolution of the drug in dimethylformamide (DMF), the ratio of the core/polymer 1:3.

Received 0,396 g white to yellowish powder. The yield was 99%.

The proposed method is suitable for the veterinary industry due to the minimal loss of speed, ease of acquisition and allocation of microcapsules.

The effectiveness of the encapsulated fenbendazol in comparison with pure fenbendazol and albendazole for treatment of strangulation the gastrointestinal tract of cattle are presented in table 1, in which:

EI - exterminationist;

AI - interenvironment;

EE - extendedrequest;

IE - intensifications.

Animals were infected by representatives of the following genera of strongest: Ostertagia, At, Cooperia, the recommended dose rate, Trichostrongylus and other

Work carried out at 55 Telco average bodyweight 318,7 kg JSC "Victory" Oktyabrsky district in may-June 2012

Animals were weighed individually at the beginning of the experiment and after 30 days. The treatment was performed by giving drugs in accordance with the weight of the bottles with water, once.

The effectiveness of the treatment was performed by counting the number of eggs of strongest 1 g of faeces individually to l the treatment and after 18 days using a counting chamber VIGIS critical test.

The table shows that the highest treatment efficiency obtained by applying the encapsulated fenbendazol (gr. 2) at a dose of 22.5 mg/kg (15 mg/kg on ADV) - EE - 94,3% and IE - 88,9%.

The effectiveness of the use of native (factory) fenbendazol (gr. 1) at a dose of 15 mg/kg on ADV was lower than in the previous group, respectively EE 7.7% and IE 5.6%.

Albendazole guidance in the dose of 15 ml per 50 kg of body weight (gr. 3) showed the efficacy of the encapsulated drug, respectively 13.2% and 8.2%.

It is noted that during the testimony of native fenbendazol a part of sedimentaries on the sides of the bottle, which is not observed in the encapsulated drug.

Average daily gain in heifers in group 1 was 0.4 kg, gr - 0,65 kg, group 3 - 0,37 kg, control 0,42 kg

Table 1
No.The name and form of the medicationDosage, mg/kgInfectionThe effectiveness of the treatmentThe relative effectiveness of HR
experimental groupsBefore the treatment After the treatment
EI, %AI, copiesEI ,%AI, copiesEE %IE %EEIE
1n-15The fenbendazol7,586,413±1,2201,7±0,037787±0,57,7-5,6
2n-15Encapsulated fenbendazol22,5 (15 A.I)86,413,5±1,76,61,5±0,0994,388,9±0,6+7,7+5,6
3n-15Albendazole 2,5%suspension15 ml/50 kgand 88.811,8±2,122,21,3±0,0471,584,4±0,513,2 -8,2
4n-10Control8012,2±0,58012,8±0,6----

Treatment of cattle with strongylata the gastrointestinal tract, which consists in using a pre-encapsulated fenbendazol, and as the shell of the microcapsules used sodium carboxymethylcellulose when receiving physical-chemical method for the deposition nerastvorim using two precipitators - carbinol and cyclohexanol, the ratio of the core/polymer 1:3, and then giving the animals at a dose of 22.5 mg/kg (15 mg/kg on ADV) once.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a method for preparing drug microcapsules of cephalosporins in konjak gum in dioxane. According to the declared method, a konjak gum solution in dioxane is added with a surfactant that is a cephalosporin powder pre-dissolved in ethanol, and with carbinol after cephalosporin forms an independent solid phase. The prepared microcapsule suspension is filtered, washed in acetone and dried in a drying oven.

EFFECT: invention enables simplifying and accelerating the process of water-soluble drug microcapsules of cephalosporins in konjak gum, as well as increasing a mass yield.

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a method for preparing drug microcapsules of cephalosporin. The method for preparing drug microcapsules of cephalosporin consists in adding a konjak solution in carbon tetrachloride with a surfactant; a powder of cephalosporin is dissolved in water or ethanol and transferred into the konjak solution in carbon tetrachloride; once the antibiotic has formed an independent solid phase, carbinol and distilled water are added drop-by-drop; the prepared suspension of microcapsules is filtered, washed in acetone and dried; the process of microcapsules is carried out in the certain environment.

EFFECT: method provides simplifying and accelerating the process of microcapsules of water-soluble drug preparations.

7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a method for preparing interferon-coated cephalosporin microcapsules. The declared method is characterized by mixing 1% aqueous solution of human leukocyte α- or β-interferon, cephalosporin powder and preparation E472c as a surfactant. The prepared mixture is stirred until the reaction components are fully dissolved, and after a transparent solution is generated, methanol 1 ml as a first non-solvent and then isopropyl alcohol 5 ml as a second non-solvent are slowly added drop-by-drop, then filtered, washed in acetone and dried.

EFFECT: invention provides preparing the high-yield cephalosporin microcapsules and ensuring the loss reduction.

8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microcapsulation of cephalosporins related to β-lactam antibiotics. A method for preparing cephalosporin microcapsules is implemented by physicochemical non-solvent addition. That involves using two non-solvents that are carbinol and isopropyl alcohol taken in ratio 1:4. The microcapsule yield makes more than 90%.

EFFECT: method for cephalosporin microcapsules provides accelerating the process for preparing and simplifying the method.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microcapsulation of drug preparations, vitamins, herbicides, flavouring agents and polysaccharides. The microcapsules are prepared by physical-chemical nonsolvent addition with using benzol as a precipitator.

EFFECT: invention provides simplifying and accelerating the process of preparing the microcapsules, reducing losses in preparing the microcapsules (higher weight yield).

48 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microcapsulation of drug preparations of cephalosporins referred to β-lactam antibiotics in konjac gum by physical-chemical precipitation in a non-solvent. Konjac gum is used as a microcapsule membrane. The microcapsules are prepared by physical-chemical precipitation in the non-solvent with using two precipitation agents - carbinol and chloroform. The process of microcapsules is carried out at 25°C with no special equipment required.

EFFECT: method according to the invention provides simplifying and accelerating the process of microcapsules of drug preparations of cephalosporins, and reducing losses (higher weight yield).

4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to microencapsulation, particularly microencapsulation of pesticides. The method consists in physical-chemical precipitation using two precipitants - butanol and ethanol. The microcapsule cladding is sodium carboxymethyl cellulose.

EFFECT: invention increases mass output of microcapsules while simplifying the process of producing microcapsules.

7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microencapsulation of drugs through the example of rivanol which can be used as an antimicrobial, antifungal topical preparation. A method for preparing microcaplues of rivanol in a water-soluble polymer representing polyvinyl alcohol or polyvinyl pyrrolidone is implemented by physical-chemical precipitation with a solvent wherein a precipitant is acetone. The process is carried out at 25°C with no special equipment required.

EFFECT: method for preparing the microcapsules of rivanol provides simplifying the process of microencapsulation.

13 dwg, 5 ex

FIELD: nanotechnology.

SUBSTANCE: device (50) for preparation of nanoparticles on a continuous basis comprises the first feeding device (1a) with the first feeding load (9) connected to the source (7) of the starting material, the first reactor (2) comprising the first heated reaction zone (13), the second reactor (3) comprising the second heated reaction zone (15), where all the said devices are connected to the channel of the material flow successively in the said order, at least one pressure control unit (18) mounted in the said channel of the material flow, a mixer (5) mounted in the said channel of the material flow between the first reactor (2) and the second reactor (3), the second feeding device (lb) with the second feeding pump (10) connected to the source (8) of the starting material, and the second feeding pump (10) is in liquid junction with the mixer (5), the control device (22) made with the ability to control the pressure value setting with the said pressure control unit (18) and/or the temperature value of the said heated reaction zones (13 and 15). The device is characterised in that after each heated reaction zone (13) in the channel of the material flow the appropriate cooling device (14, 16) is mounted for reducing the size of the nanoparticles in the process of their preparation, and the cooling devices (14, 16) are additionally made with the ability to cease this process of nanoparticles preparation. Also the invention relates to use of the device for preparation of nanoparticles/nanoemulsions/colloidal solutions.

EFFECT: invention enables to obtain nanoparticles which properties can be modified in the course of this process.

8 cl, 10 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical microcapsulation of cephalosporins related to β-lactam antibiotics. As a microcapsule shell, the method of pharmaceutical microcapsulation of cephalosporins uses konjac gum; the microcapsules are prepared by physical-chemical technology implying the precipitation in a non-solvent using two precipitants - carbinol and diethyl ester in ratio 1:3; the method is conducted at 25°C with no special equipment.

EFFECT: invention provides simplified and accelerated preparation of the water-soluble pharmaceutical microcapsules of cephalosporins in konjac gum, loss reduction in preparing the microcapsules (higher yield-mass).

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, particularly to methods for preparing immunometabolic preparations with anthelminthic activity. The method involves adding levamisole, succinic acid and citric acid to demineralised water in the amounts specified in the patent claim. The preparation is used for parenteral infusion in a dose of 1 ml per 10 kg of animal's body weight.

EFFECT: complex preparation possesses high antioxidant, immunometabolic and anthelminthic action.

3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to using common dandelion herb as a trematocidal drug for excysted larvae Fasciola hepatica.

EFFECT: common dandelion herb is effective as a trematocidal drug for excysted larvae Fasciola hepatica.

2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical composition used in treating new growths and containing: artemisinin, artemether, arteether, artenimol or artesunate and a pharmaceutically acceptable excipient specified in a group consisting of: medium-chain triglycerides, short-chain triglycerides; omega-3-marine triglycerides; and cod liver oil high in omega-3-fatty acids wherein the above composition is presented in the form of a preparation for transmucosal, sublingual, buccal or nasal dosage.

EFFECT: provided high bioavailability and stability; prevented self-induction.

15 cl, 11 tbl, 14 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmaceutical industry, particularly to an agent for preventing and treating opisthorchiasis. The agent for preventing and treating opisthorchiasis on the basis of herbal extract containing an aqueous and/or lipid complex of pine and fir straw as herbal extract and an active ingredient.

EFFECT: agent is effective for preventing and treating opisthorchiasis.

6 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: treatment is performed in three stages. At the first stage preparatory treatment is carried out for 7 days, for which purpose intake of antihelmintic of vegetable origin and immunomodulator, intestinal lavage and procedures according to the programme of resonance-acoustic oscillations (PRAO) are carried out, as well as mud therapy - applications of the region of liver- and radon baths. At the second stage dehelmintisation is carried out for 7 days, for which purpose intake of antihelmintic of vegetable origin and immunomodulator, procedures in salt chamber, procedures according to PRAO, as well as radon baths are carried out. At the third stage 7-day long rehabilitation treatment is carried out, for which purpose intake of antihelmintic of vegetable origin and immunomodulator, intestinal lavage, procedures according to PRAO, microclysters with bifidobacteria and mud treatment - applications on the region of liver are carried out. Mini-sauna "Cedar barrel" and radon baths are taken.

EFFECT: method makes it possible to achieve complete dehelmintisation and reliable rehabilitation due to complex influence on all links of systemic process pathogenesis of parasitic invasion.

4 cl, 3 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: invention relates to veterinary and is intended for fighting carp bothriocephalosis in fish farms on water reservoirs coolers of thermal and nuclear power stations. Method of obtaining anti-helminth medication against fish bothriocephalosis is characterised by the following: niclosamide is introduced into propyleneglycol in ratio 3:1, solution is brought to boiling and mixed until niclosamide completely dissolves, after which, filling agent - zeolite tufa - is added in ratio 1:4 with thorough mixing until filling agent is completely impregnated.

EFFECT: invention ensures reduction of therapeutic dose and forage toxicity.

3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to organic chemistry and a novel biologically active substance - N-(3,4-dichlorophenyl)-2-acetoxy-3,5-dichlorobenzamide which exhibits high anthelmintic activity, which enables to use the disclosed compound in medicine and veterinary.

EFFECT: obtaining a compound with high anthelmintic activity.

1 cl, 4 ex, 2 tbl

FIELD: chemistry.

SUBSTANCE: disclosed is a novel biologically active salicylanilide derivative and specifically N-(3-chloro-4-propyloxyphenyl)-3,5-dichlorosalicylamide.

EFFECT: obtaining a compound having high anthelmintic activity with low toxicity, which enables to use the disclosed compound in medicine and veterinary.

1 cl, 3 ex, 1 tbl

FIELD: veterinary medicine.

SUBSTANCE: agent comprises, wt %: univerm - 20.0; albendazole - 2.5, carboxymethyl cellulose sodium salt - 0.5, and water - the rest. The agent is administered orally at a dose of 0.8-1.0 ml/kg of body weight as a single dose, individually.

EFFECT: group of inventions enables to reduce the frequency of treatments of animals, to improve effectiveness of antiparasitic activities.

2 cl, 6 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to field of veterinary. Medication contains anti-helminth preparation nilverm, oxyclosanide, phosphogypsum and calcium carbonate in the following component ratio, wt %: nilverm - 0.5-0.6; oxyclosanide - 0.1-0.15; phosphogypsum - 70-75; calcium carbonate - the remaining part.

EFFECT: medication has lower toxicity, high anti-helminth efficiency, is a source of making up for the deficit of macro- and microelements in animal organism.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to drug microencapsulation, particularly for preparing fenbendazole microcapsules. The method is characterised by the fact that a microcapsule coating is carboxymethyl cellulose; fenbendazole dissolved in dioxane or dimethyl sulphoxide (DMSO), or dimethyl formamide (DMFM) is dispersed into the solution of sodium carboxymethyl cellulose in dioxane in the presence of the preparation E472c; further, isopropanol and distilled water are added; the prepared microcapsule suspension is filtered and dried; a process of microcapsules is conducted at 25°C for 20 minutes with no special equipment; with nucleus/polymer ratio making 1:3.

EFFECT: invention provides simplifying and accelerating the process of preparing the fenbendazole microcapsules in carboxymethyl cellulose, reducing losses in preparing the microcapsules (higher weight yield).

3 ex

Up!